GLP-1 medications have been shown to reduce liver fat content and overall liver volume, leading to improved visualization and safer surgical dissection
As metabolic drug discovery continues to evolve, how might access to human L-cell secretion change early screening, target selection, and program differentiation
Baumgardner JN, Shankar K, Hennings L, et al
(Sanja Strbe): validation
Voy, which has had several previous complaints upheld by the ASA concerning the promotion of weight loss drugs, told the ASA it has addressed the error internally and reinforced controls to prevent specific POMs being referenced in future marketing communications
While these breakthrough treatments can significantly improve health outcomes, our patients and people on forums like Reddit share mounting concerns about accessibility